Legend Biotech Corp
LEGN
Company Profile
Business description
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Contact
2101 Cottontail Lane
SomersetNJ08873
USAT: +1 737 317-5050
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,700
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,813.00 | 28.90 | -0.33% |
| CAC 40 | 7,696.27 | 58.28 | -0.75% |
| DAX 40 | 23,787.45 | 146.68 | -0.61% |
| Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
| FTSE 100 | 8,822.91 | 0.29 | -0.00% |
| HKSE | 23,821.51 | 94.55 | -0.40% |
| NASDAQ | 20,601.10 | 207.97 | 1.02% |
| Nikkei 225 | 39,628.41 | 182.47 | -0.46% |
| NZX 50 Index | 12,758.95 | 7.65 | -0.06% |
| S&P 500 | 6,279.35 | 51.93 | 0.83% |
| S&P/ASX 200 | 8,573.20 | 29.80 | -0.35% |
| SSE Composite Index | 3,465.40 | 6.92 | -0.20% |